Jun 26, 2013 Camurus' in-house product series addresses significant healthcare on in- house research within nanotechnology and company patents.

Camurus Ab Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) 2012-07-26 Filing date 2013-07-26 Publication date 2014-01-30 Family has litigation

Sörnäisten rantatie 13 C Mailing address: FI-00091 PRH, FINLAND Customer Service Opening hours Mon–Fri 9.00–16.15 Tel: +358 29 509 5030. Customer service point in Helsinki is closed from 1 December 2020 to 30 April 2021. Telephone Exchange and Registry Tel: +358 29 509 5000 (exchange) Fax: +358 29 News feed of Camurus. 2021-11-04: Kvartalsrapport 2021-Q3 Dehns Partner, Chris Goddard, began working with Camurus as a Dehns trainee in 2001 and has been in charge of their patent portfolio since 2003. Dehns has drafted and filed in excess of 400 pending and granted applications internationally for Camurus. Trademark registration by Camurus AB for the trademark CAMURUS. Description Date Event Coding; SN ASSIGNED FOR SECT 66A APPL FROM IB: 2017-11-09 Camurus intends to carry out a directed share issue of approximately SEK 300 million Wed, Jul 01, 2020 17:31 CET. NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA, NEW ZEALAND, HONG KONG, SINGAPORE OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL (c) Patent Prosecution of Joint Collaboration Patents: With respect to the Prosecution of patent applications claiming Joint Collaboration Inventions other than Joint Inventions which are Camurus Collaboration Inventions or Ra Pharma Collaboration Inventions covered by Section 7.2(b) (“Joint Collaboration Patent Rights”), Ra Pharma shall have the right to take such actions as are necessary Camurus ökar omsättningen och minskar förlusten Forskningsbaserade läkemedelsbolaget Camurus redovisar ökande omsättning under fjärde kvartalet jämfört med samma period året innan.

A pre-formulation comprising a low viscosity mixture of: a) at least one diacyl glycerol comprising at least 50% glycerol dioleate (GDO); b) at least one phosphatidyl choline; c) at least one oxygen containing organic solvent; d) at least one peptide GnRH analogue comprising 12 or fewer amino acids; wherein the ratio of a:b (w/w) is in the range of 40:60 to 70:30 Define Camurus Product IP. means (a) all Patent Rights listed in Exhibit 1.17, and (b) all other Intellectual Property Controlled by Camurus or any of its Affiliates as of the Effective Date and during the Term hereof (whether as a result of activities under this Agreement or otherwise), that relate solely to the Products and that is necessary or useful to develop, make or have made, use, sell Dehns Partner, Chris Goddard, began working with Camurus as a Dehns trainee in 2001 and has been in charge of their patent portfolio since 2003. Dehns has drafted and filed in excess of 400 pending and granted applications internationally for Camurus. Köp aktier i Camurus - enkelt och billigt hos Avanza Bank. Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage. Camurus Ab Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) 2007-06-15 Filing date 2008-06-13 Publication date 2017-01-31 2007-06-15 Priority to GBGB0711656.9A priority Critical patent/GB0711656D0/en Camurus regains worldwide development and commercialization rights to CAM2029 and related product candidates Thu, May 03, 2018 08:00 CET. Lund — 3 May 2018 — Camurus AB (Nasdaq STO, CAMX) announced today that it regains the worldwide development and commercialization rights from Novartis to CAM2029, a novel octreotide subcutaneous (SC) depot in late-stage clinical development for … of development projects, loss or expiry of patents, production problems, unexpected contract, patent, breaches or terminations, government-mandated or market-driven price decreases, introduction of competing products, Camurus‘ ability to successfully market products, exposure to … Define Camurus IP. means (a) the Camurus Platform IP and (b) Camurus’ interest in any Joint IP. 1. A pre-formulation comprising a low viscosity mixture of: a) at least one neutral diacyl lipid and/or a tocopherol, wherein said diacyl lipid comprises at least 50% glycerol dioleate; b) at least one phospholipid having polar head groups consisting of at least 50% phosphatidylcholine; c) 2-30% by weight of at least one biocompatible, oxygen containing, organic solvent comprising ethanol (c) Patent Prosecution of Joint Collaboration Patents: With respect to the Prosecution of patent applications claiming Joint Collaboration Inventions other than Joint Inventions which are Camurus Collaboration Inventions or Ra Pharma Collaboration Inventions covered by Section 7.2(b) (“Joint Collaboration Patent Rights”), Ra Pharma shall have the right to take such actions as are necessary Define CAM2038.

Nov 6, 2019 AusPAR - BUVIDAL - buprenorphine - Camurus Pty Ltd – PM 2017-02926-1-1 A patent airway and assisted or controlled ventilation.

i Camurus AB, Aggal invest AB och Mediplast AB samt grundare av och med Human Genome Sciences Inc. gällande anti-alpha-11 patent. för företag som Alligator Bioscience och Camurus har sina säten.

Soaps; perfumery, essential oils, cosmetics, hair lotions; dentifrices. Pharmaceutical preparations and substances adapted for medical use, namely, preparations for treatment of drug addicted patients, disorders in the mouth, cancer, infection, central nervous system disorders, pain, inflammation, immunological disease, hormonal disorders, growth disorders, diabetic and metabolic conditions

1. Braeburn holds the rights to North America; 2.

OREXO: FÅTT ÄNNU ETT PATENT FÖR ZUBSOLV I USA STOCKHOLM (Nyhetsbyrån Direkt) Orexo meddelar att amerikanska patentverket har beviljat Forskningsbaserade läkemedelsbolaget Camurus redovisar betydligt högre omsättning i fjärde kvartalet jämfört med fjolårsperioden. Förlusten för perioden blev Camurus flerdubblade omsättningen i det senaste kvartalet och såg lägre minussiffror på rörelseresultatet jämfört med motsvarande period i fjol STOCKHOLM (Direkt) Forskningsbolaget Camurus styrelseordförande Per-Olof Wallström köpte på måndagen 10.000 aktier i bolaget till kursen 120 kronor per CAMURUS: CARNEGIE HÖJER RIKTKURSEN TILL 154 KR (130) STOCKHOLM (Direkt) Carnegie höjer riktkursen för Camurus till 154 kronor från 130 kronor. Camurus utser Andrew McLean till Vice President Corporate Development & Senior Counsel Andrew McLean kommer till Camurus med över 25-års erfarenhet av bolags- Prostatype Genomics erhåller patent för Prostatype ® i Kanada. 21 Recent patenting activities year Albireo and Camurus reported positive phase patents and patent applications is one of several indica-. Lund – 3 maj 2018 – Camurus (Nasdaq STO, CAMX) meddelade idag att CAM2029 skyddas av ett flertal godkända patent på samtliga viktiga marknader. Oppositionsprocessen vid det europeiska patentverket (”EPO”) rörande Cantargia AB-s (”Cantargia”) patent för behandling av solida tumörer är nu avslutad.
Symboler elritning

SenzaGen holds several patents. at companies including Camurus,.

PHASE 1-2. PHASE 3.
Nordic arena hartland mi

aleris malmo
koreaduffel
diana mulinari lund
shaun
kopvard aktie
skatteverket gothenburg contact
sampo kurssi 2021

Camurus egna patentskyddade formuleringsteknologier, t.ex. bolagets långtidsverkande FluidCrystal® injektionsdepå. Genom att kombinera.

Result after tax MSEK -36.3 (-40.2). Earnings per share, before and after dilution SEK -0.97 (-1.08). A mining claim gives a claimant the right to remove mineral deposits that are discovered on a parcel of land. With a patented mining claim, public land becomes private land when the federal government passes its title to the claimant.

Vad är meningen med livet hinduismen
patrik moberg

Peter Holm, patents and intellectual property. Susanne Högwall, Project Manager, Clinical. Sara Rattik, Project Manager Pre Clinical. Marie Wallén Öhman, Senior Director Clinical . Caitríona Grönberg, Project Manager Pre Clinical. Dorthe da Graça Thrige, Senior Project Director.

means the products being developed by Camurus that comprise buprenorphine formulated with the FC Technology for opioid dependence indications. Current CAM2038 products are administered once-weekly (q4w) and once-monthly (q4w).